A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Bristol-Myers Squibb
Takeda
National Cancer Institute (NCI)
Vejle Hospital
Pfizer
Akeso
Seagen Inc.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Duke University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Enliven Therapeutics
Jiangsu HengRui Medicine Co., Ltd.
City of Hope Medical Center
Akeso
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Pfizer
Sun Yat-sen University
DEKA Biosciences
UNICANCER
Helsinki University Central Hospital
Rutgers, The State University of New Jersey
Ono Pharmaceutical Co., Ltd.
Sun Yat-sen University